Opioid Addiction Indication Could Offer Fix For Alkermes' Troubled Vivitrol
Executive Summary
Alkermes' four-year-old Vivitrol has been struggling to get its head above water as a therapy for alcoholism. But fast-track status for a new opioid addiction indication and a slew of supportive studies at the American Psychiatric Association meeting offer the $900-a-month injectable a shot at recovery
You may also be interested in...
Vivitrol's Opioid Abuse Claim Will Likely Need Monitoring and Support Services
FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of expanding the indication for Alkermes' alcoholism treatment by lopsided margins, with the caveat that monitoring and support must be provided to patients.
For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love
Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.
Alkermes' Vivitrol For Opioid Dependence Could Be Dealt Wild Card At Advisory Committee
Expert panels have recently shown they may think differently from FDA on the subject of opioids..